US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
This article was originally published in The Pink Sheet
Executive Summary
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
You may also be interested in...
CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA
CHPA says CBO's five-year $232m estimate for the costs of compliance with the DXM Abuse Prevention Act is too high since it is based on costs of FDA's tobacco compliance check program. CBO says the bill would have a minimal cost impact on retailers, since many already restrict sales.
Education To Prevent Abuse Reinforces DMX Safety As OTC – CHPA Study
Trade group's journal shows how its targeted campaign is likely influencing teens’ perceptions of DXM abuse.“Bait-and-switch” approach aims to educate teens looking online for information on how to abuse cough/cold OTC medications.
Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.